Investigational drug · Phase 3
CBL-514
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Subcutaneous Fat, Dercum's Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
5 still active
All registered trials
16
Any phase or sponsor naming "CBL-514"
First trial start
2024
Nov 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CBL-514", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- Subcutaneous Fat
- Dercum's Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "CBL-514" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous FatPivotal-lookingRecruiting
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT07140939 · 320 participants (planned) · Start Sep 1, 2026 · Primary completion Jul 2027
Drug: CBL-514 Injection · For: Subcutaneous Fat
Sites: Encinitas, California; West Palm Beach, Florida; Chicago, Illinois · 13 sites in all
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )Pivotal-lookingRecruiting
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT07526974 · 320 participants (planned) · Start Nov 9, 2026 · Primary completion Aug 2027
Drug: CBL-514 Injection; 0.9% Sodium Chloride · For: Subcutaneous Fat
Sites: Encinitas, California; Aventura, Florida; Miami, Florida · 15 sites in all
- A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)Pivotal-lookingNot yet recruiting
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT07733947 · 300 participants (planned) · Start Dec 2026 · Primary completion Aug 2028
Drug: CBL-514 Injection; 0.9 % sodium chloride · For: Subcutaneous Fat
Sites: Encinitas, California
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatPivotal-lookingRecruiting
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT07608770 · 250 participants (planned) · Start Jun 1, 2026 · Primary completion Apr 2027
Drug: CBL-514 Injection; 0.9% Sodium Chloride · For: Subcutaneous Fat
Sites: South Yarra, Australia
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatNot yet recruiting
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT07608757 · 250 participants (planned) · Start Feb 2027 · Primary completion Feb 2028
Drug: CBL-514 Injection · For: Subcutaneous Fat
Sites: South Yarra, Australia
- A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.Pivotal-lookingCompleted
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT06005441 · 173 participants · Start Nov 10, 2023 · Primary completion Oct 18, 2024
Drug: CBL-514 injection; CBL-A1 Injection and 2 more · For: Subcutaneous Fat
Sites: Omaha, Nebraska
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatPivotal-lookingCompleted
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT05736107 · 107 participants · Start May 30, 2023 · Primary completion May 20, 2024
Drug: CBL-514 Injection · For: Subcutaneous Fat
Sites: Pflugerville, Texas
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT04897412 · 75 participants · Start Feb 14, 2022 · Primary completion Feb 22, 2023
Drug: CBL-514 Injection · For: Subcutaneous Fat
Sites: Chicago, Illinois; Omaha, Nebraska; Nashville, Tennessee · 5 sites in all
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT04698642 · 43 participants · Start Feb 3, 2020 · Primary completion Nov 12, 2020
Drug: CBL-514 · For: Subcutaneous Fat
Sites: Melbourne, Australia
Caliway Biopharmaceuticals Co., Ltd.Industry
NCT04699669 · 40 participants · Start Nov 27, 2018 · Primary completion Aug 20, 2019
Drug: CBL-514, placebo; CBL-514, placebo and 1 more · For: Subcutaneous Fat
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- A Systematic Review of Injectable Lipolytic Agents for Nonsubmental Fat Reduction.
Carrion K, Salingaros S, Bernal C, et al. · Plast Reconstr Surg 2026
- Dercum's Disease: A Practical Review of Existing and Novel Therapies.
Idris YA, Janis JE · Plast Reconstr Surg Glob Open 2026
- Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment.
Lorenc ZP, Gold M, Schlessinger J, et al. · Aesthet Surg J 2026
- Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study.
Herbst KL, Ling YF, Sheu AY, et al. · JAAD Int 2026
- Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.
Gold M, Schlessinger J, Goodman GJ, et al. · Aesthet Surg J 2025
- Modern and Non-Invasive Methods of Fat Removal.
Piat P, Szpila G, Stojko M, et al. · Medicina (Kaunas) 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.